A group of independent advisers to the U.S. Food and Drug Administration cast their votes Friday against adding the peptide emideltide to a list that would permit wider compounding by pharmacies.
The outcome was a narrow one — seven panel members voted to keep emideltide off the list, while six members supported its inclusion. A fourteenth member chose to abstain from the vote.
The decision reflects ongoing regulatory scrutiny over which substances can be compounded more broadly, a process that allows pharmacies to prepare customized medications outside of standard manufacturing channels.
